Hypertrophic Cardiomyopathy Clinical Trials

The hypertrophic cardiomyopathy (HCM) clinical trials team is interested in seeing how exciting new HCM drugs can help to improve the outcomes and quality of life for those living with the HCM disease.

Feel free to call or e-mail the Knight Cardiovascular Institute research team at 503-418-1964 or by emailing heartresearch@ohsu.edu. You will then be forwarded to the appropriate research team member who will be able to see if you qualify for any of the clinical trials being offered at OHSU. 

You can also find all the of heart failure clinical trials, that are currently enrolling patients, below.

HCM Pilot Study

Hypertrophic Cardiomyopathy Pilot Study

Primary investigator:

Larisa Tereshchenko, M.D., Ph.D.

Sub investigators:

Protocol number:

IRB00015049

Study purpose:

This study evaluates mechanisms of arrythmogenicity in hypertrophic cardiomyopathy, in comparison to patients with well-understood arrhythmogenic substrate (ischemic cardiomyopathy), as well as to individuals free from arrhythmogenic substrate.

Contact:

Nichole Rogovoy (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

LIVE-HCM/LIVE-LQTS

Exercise in Genetic Cardiovascular Conditions

Primary investigator:

Stephen Heitner, M.D.

Sub investigators:

Protocol number:

IRB00012026

Study purpose:

The purpose of this study is to learn about cardiac events in subjects with Hypertrophic Cardiomyopathy and Long QT Syndrome who participate in different levels of activity.

Contact:

Megan Wasteney (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

MAVERICK-HCM

A Randomized, Double-blind, Pacebo-controlled, Concentration-guided, Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

Primary investigator:

Stephen Heitner, M.D.

Sub investigators:

Protocol number:

IRB00018173

Study purpose:

The purpose of this study is to evaluate the effect of the investigational drug, mavacamten, compared to a placebo (an inactive drug) in patients with non-obstructive HCM. This is being done to confirm that mavacamten is safe, and can be tolerated and to study whether it helps to improve symptoms or ability to exercise.

Contact:

Katie McCullough (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu